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A Polymorphic Pocket at the P10 Position
Contributes to Peptide Binding Specificity
in Class II MHC Proteins
ets in the peptide binding groove are spaced to accom-
modate some of the peptide side chains, with the re-
mainder held accessible for interaction with T cell
receptors. In structures of human and mouse class II
MHC proteins, pockets within the overall peptide bind-
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and Molecular Pharmacology Pockets are numbered along the peptide relative to a
University of Massachusetts Medical School large hydrophobic pocket near the peptide binding site.
Worcester, Massachusetts 01655 These positions are consistent with experimentally de-
3 Blood Research Institute termined peptide binding motifs, which indicate peptide
Blood Center of Southeastern Wisconsin sequence preferences at these positions [13, 14].
Milwaukee, Wisconsin 53201 Class II MHC proteins are highly polymorphic in all
species that express them. Over 400 alleles have been
characterized for the  subunit of HLA-DRB, the most
Summary highly expressed of the three human class II MHC pro-
teins [15]. (The  subunit is nonpolymorphic). Most of
Peptides bind to class II major histocompatibility com- the polymorphisms can be found in positions that corre-
plex (MHC) proteins in an extended conformation. spond to the residues lining the pockets within the pep-
Pockets in the peptide binding site spaced to accom- tide binding site. The allelic differences influence the
modate peptide side chains at the P1, P4, P6, and P9 peptide binding specificity of the various class II MHC
positions have been previously characterized and help alleles and thus determine allele-specific differences in
to explain the obtained peptide binding specificity. the spectrum of peptides presented to the immune sys-
However, two peptides differing only at P10 have sig- tem. These differences have important consequences
nificantly different binding affinities for HLA-DR1. The for susceptibility to autoimmune diseases, resistance to
structure of HLA-DR1 in complex with the tighter bind- infection, vaccine efficacy, and rejection of transplanted
ing peptide shows that the peptide binds in the usual organs and administered proteins [16]. In the common
polyproline type II conformation, but with the P10 resi- allelic variant HLA-DR1 (DRB1*0101), for example, the
due accommodated in a shallow pocket at the end of P1 pocket shows strong preferences for large hydropho-
the binding groove. HLA-DR1 variants with polymor- bic residues (such as Tyr, Trp, Phe, Leu, and Ile), the
phic residues at these positions were produced and P6 pocket prefers smaller residues (Gly, Ala, Ser, and
found to exhibit different side chain specificity at the Pro), and the P4 and P9 pockets tend to have weaker
P10 position. These results define a new specificity preferences for residues that have aliphatic character
position in HLA-DR proteins. [14]. Algorithms designed to predict peptide binding
affinities for HLA-DR1 and for other class II MHC allelic
Introduction variants have been developed based on experimental
peptide and phage display binding data together with
Major histocompatibility complex (MHC) proteins play
the pattern of MHC-peptide side chain contacts ob-
an important role in the generation of immune responses
served in the crystal structures [17–20]. Generally, such
by binding peptide antigens and presenting them at the
approaches have considered only positions P1–P9 or acell surface for inspection by antigen receptors on T cells
subset of these positions, although one report analyzed[1]. T cell recognition of MHC bound antigens is required
specificity at positions P1–P10 by using randomizedfor the generation of adaptive immune responses
peptide libraries [21].against pathogenic viruses, bacteria, and fungi, and for
A recent study of HLA-DR52a (HLA-DRB3*0101)selection and maintenance of the large repertoire of
bound to an integrin 3-derived peptide suggested acirculating T cells. Class II MHC proteins are found in
role for the P10 position in peptide binding [22], and amacrophages, B cells, dendritic cells, and other “anti-
similar effect was observed in a systematic study ofgen-presenting cells” of the immune system, where they
contributions of anchor and nonanchor positions to thebind peptides produced by endosomal proteolysis. The
overall peptide binding affinity of HLA-DR1 [23]. Here,endosomal antigen-processing machinery results in a
we have investigated the structural basis for specificitylarge variety of peptide antigens bound to class II MHC
at the P10 position of peptides bound to HLA-DR1. Aproteins, with an average length of 15–20 residues [2,
newly described shallow pocket or shelf on the edge of3]. Peptides bind to class II MHC proteins in an extended
the MHC peptide binding site interacts with peptide P10conformation, with up to 12 peptide residues in direct
side chains, and common MHC polymorphisms in thiscontact with the MHC peptide binding groove [4]. Pock-
region alter the peptide side-chain specificity. These
results suggest that the P10 position can play an impor-*Correspondence: lawrence.stern@umassmed.edu
4These authors contributed equally to this work. tant role in MHC peptide binding selectivity.
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would appear to be due to an interaction between the
peptide P10 residue and HLA-DR1. As noted above, a
side-chain binding pocket at this position has not been
described in HLA-DR1 or any other class II MHC protein,
and peptide binding motifs generally do not include a
side chain preference at this position. It is possible,
however, that these peptides bind in an expected con-
formation, or that one (or both) of the peptides binds in
an unexpected register or conformation; for example,
the peptide might “bulge,” as observed in complexes
of peptides bound to class I MHC proteins [24], shifting
the peptide side chains that are accommodated in the
MHC pockets. To elucidate the structural basis for the
apparent specificity at the P10 position, we crystallized
HLA-DR1 in complex with the AAYSDQATPLLLSPR
peptide and determined its structure by X-ray diffraction
methods.
Crystal Structure of HLA-DR1 Reveals a P10
Shallow Pocket or Shelf
The X-ray crystal structure of HLA-DR1 bound to the
AAYSDQATPLLLSPR peptide was determined in two
crystal forms, one with two molecules in the asymmetric
unit, and another with one molecule in the asymmetric
unit in complex with the bacterial superantigen SEC3-
3B2 that has been used previously to facilitate crystalli-
zation of HLA-DR variants (Table 1). SEC3-3B2 makes
contacts with the  chain of HLA-DR1 outside the bind-
ing site and does not contact the peptide [25, 26]. In
each of the structures, clear and continuous density
was observed for essentially all of the MHC protein,
excluding a disordered loop away from the peptide bind-
ing site, and also for all of the bound peptide from theFigure 1. The P10 Position of Peptides Can Affect Binding to HLA-
P2 to P11 positions (Figures 2A and S1; see the Supple-DR1
mental Data), excluding the P8 Leu side chain, which is(A) Surface of the HLA-DR1 peptide binding site with bound AAYSD
oriented toward the T cell receptor and does not contactQATPLLLSPR peptide shown as a stick model. In the peptide, car-
bon atoms are yellow, nitrogen atoms are blue, and oxygen atoms the MHC, and the C1 and C2 terminal methyl groups
are red. Peptide side chain binding pockets are labeled. of the P10 Leu side chain. The peptide binds in the usual
(B) Competitive binding analysis of two peptides that differ only in polyproline type-II conformation, using the expected an-
the P10 position. A fixed concentration of peptide-free HLA-DR1 chor residues Tyr (P1), Gln (P4), Thr (P6), and Leu (P9)and biotinylated Ha peptide was incubated with increasing concen-
(Figure 2A). As commonly observed in class II MHCtrations of either AAYSDQATPLLLSPR or AAYSDQATPLLGSPR
peptide structure, the peptide termini outside the bind-peptide. After binding for 3 days at 37C, the amount of biotinylated
Ha peptide/HLA-DR1 complexes was measured with alkaline phos- ing site were disordered. The MHC and peptide portions
phatase-labeled streptavidin in an antibody-capture assay. of these structures were identical in the three views of
the molecule provided by these crystals, except for
some crystal contacts that vary between the crystals
forms (Figure 2B). We were not able to obtain crystalsResults and Discussion
of HLA-DR1 in complex with the other peptide (AAYSD
QATPLLGSPR).The P10 Position Can Influence Binding
of Peptides to HLA-DR1 The peptide P10 residue and the area surrounding the
MHC region were well-resolved in each of the crystalTwo peptides with sequences differing only by a single
amino acid predicted to occupy the P10 pocket (AAYSD forms, with the exception of the terminal methyl groups
of the P10 Leu. HLA-DR1 residues located in close prox-QATPLLLSPR and AAYSDQATPLLGSPR) bind to HLA-
DR1 with 15-fold different apparent affinity as measured imity to the P10 side chain are Arg76, Pro56, Asp57,
and Tyr60 (Figure 2C). These residues form a shallowby a competition assay (Figure 1B). The peptide se-
quences derive from the integrin 3 peptide previously pocket or “shelf” that accommodates the P10 residue
(Figure 2D). The interaction buries 117 A˚2 of solventimplicated in P10 effects in the context of HLA-DR52a
[22], but with the “anchor” P1, P4, P6, and P9 positions accessible surface area from the Leu (P10) residue (of
1220 A˚2 that is buried from the entire peptide), andchanged to the corresponding residues from the influ-
enza haemagglutin [306–318] peptide (HA), a well-char- 73 A˚2 of solvent accessible surface area from the MHC
(of 850 A˚2 that is buried by interaction with the entireacterized viral antigen that binds tightly to HLA-DR1 (Kd
of10 nM) [12]. The difference in peptide binding affinity peptide). Essentially all of the MHC surface area buried
A Class II MHC Binding Pocket at the P10 Position
1397
Table 1. Data Collection and Refinement Statistics
Crystal
Parameters HLA-DR1/AAYSDQATPLLLSPR HLA-DR1/AAYSDQATPLLLSPR/SEC3-3B2
Space Group C2221 R3
Cell Dimensions
a,b,c (A˚) 96.55,112.65,172.75 173.21,173.21,121.54
Data
Collection Overall Highest Res. Shell Overall Highest Res. shell
Resolution limits (A˚) 24.0–2.40 2.49–2.40 30.0–2.40 2.49–2.40
Unique reflections 44,505 4384 53,191 5,392
Total reflections 252,441 20,869 319,169 30,576
Completeness (%) 99.8 99.8 99.9 100.0
Mean I/ (I ) 11.0 3.5 9.7 2.0
Rsym (%)a 6.5 37.8 11.4 49.7
Refinement
Rfreeb 25.6 38.1 24.1 34.9
Rcryst 23.1 31.8 20.8 31.2
Model Average B Factor (A˚2) # Residues (Atoms) Average B Factor (A˚2) # Residues (Atoms)
HLA-DR1 39.8 737 (6070) 39.9 368 (3027)
Peptide 51.5 26 (188) 47.4 13 (94)
SEC3-3B2 N/A N/A 39.4 229 (1884)
Waters 40.9 166 42.0 287
Estimated Coordinate Error
Luzatti (A˚) 0.32 0.37
Sigma A (A˚) 0.31 0.34
RMSD
MHC (A˚) 0.054c 0.28d
Peptide (A˚) 0.034c 0.24d
Ramachandran Plot
Core  Allowed (%) 99.7 99.8
Generous (%) 0.0 0.2
a Rsym  |I  	I
|/	I
, where I is the observed intensity and 	I
 is the average intensity of multiple observations of symmetry-related
reflections.
b R factor on structure factors for reflection omitted from the refinement and used as a test set (10% of total).
c Relationship between the MHC or peptide components of the two NCS-related molecules in the asymmetric unit.
d Relationship between the MHC or peptide components of the R3 crystal form as compared to molecule 1 of the other crystal form. Values
for molecule 2 are essentially identical
by the P10 residue is hydrophobic. The fraction buried assay (Figure 3A). The peptide sequence is similar to
that used in the structural work described above, exceptfor the residue at P10 is 0.63, which is comparable to
the fraction buried for residues in the P3 (0.65), P4 (0.69), that (P7) was changed to the more favorable Leu (P7),
eliminating possible backbone conformational and en-and P7 (0.77) pockets. Crystal structures are currently
available for six other HLA-DR molecules in complex tropic effects unique to proline (I.S., Z.Z.-R., and L.J.S.,
unpublished data). Peptide binding competition IC50 val-with peptides that extend to the P10 position. In each
of these, the residues that line the P10 pocket are orga- ues are shown in Table S1 (see the Supplemental Data)
and are plotted in Figure 3B relative to the average ofnized essentially identically to the complex reported
here (Figure S2A; see the Supplemental Data). In each all peptides in the series. Clearly there is peptide side
chain specificity at the P10 position, with phenylalaninecase, the P10 residue is substantially buried in the
pocket (with the exception of DRB5*0101 in complex and tyrosine strongly preferred and asparagine, proline,
and serine disfavored.with a peptide from Epstein-Barr virus, where the pep-
tide binds in an unusually extended conformation with
the P9 residue contacting the P10 pocket) (Figure S2B). Allelic Polymorphism at the P10 Region
of HLA-DR
Inspection of the HLA-DR1 structure in the vicinity ofBinding Specificity to the P10 “Shelf” on HLA-DR1
In order to explore peptide binding specificity for the the P10 shelf shows that the residues Arg76, Pro56,
Asp57, and Tyr60 play the major roles in formationP10 side chain, we synthesized a set of peptides that
contained the AAYSDQATLLLXSPR sequence, where X of the shelf and interaction with the peptide (Figures 2C
and 2D). Arg76 is part of the nonpolymorphic  subunit,is one of the 20 natural amino acids, and measured their
relative affinity for HLA-DR1 in a competition binding and Pro56 is conserved within all the HLA-DR alleles,
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Figure 2. Crystal Structure of HLA-DR1
Bound to AAYSDQATPLLLSPR
(A) 2Fo-Fc electron density map contoured
at 1 using data in the resolution rage of
30–2.4 A˚, with all peptide atoms omitted from
the map calculation. The peptide carbon
atoms are yellow, and nitrogen and oxygen
atoms are blue and red, respectively.
(B) The AAYSDQATPLLLSPR peptide from
the HLA-DR1/SEC3-3B2 complex (carbon
atoms colored in yellow) was superimposed
with the peptides present in the structure of
HLA-DR1 without the superantigen (carbon
atoms colored in green or magenta for the
two molecules in the asymmetric unit).
(C) 2Fo-Fc electron density maps contoured
at 1 for the P10 region of HLA-DR1/AAYSD
QATPLLLSPR. (All the labeled residues were
omitted from the map calculation). The car-
bon atoms for the peptide are yellow, and the
ones for HLA-DR1 are green. The view is from
the right side of (A), with the  subunit helix
to the right and the  subunit helix to the left.
(D) Surface of the HLA-DR1 P10 region shown
with the same view as (C). Residues lining the
pocket are labeled. Residues 57 and 60
are polymorphic among HLA-DR proteins.
Figures were generated with PyMol [43].
but Asp57 and Tyr60 are highly polymorphic (Table
S2). In the context of other class II MHC proteins, poly-
morphism at Asp57 has been linked to human (HLA-
DQ) and murine (I-Ag7) diabetes [5, 8].
We attempted to evaluate the effect of these polymor-
phisms on peptide side chain specificity at the P10 posi-
tion by using published studies. The influence of 57
and60 on HLA-DR peptide binding specificity has been
studied systematically as part of a pocket-based matrix
approach to epitope prediction [17], but the P10 pocket
was not included in the analysis. For I-Ag7, a mouse class
II MHC protein, it has been suggested that polymor-
phism at 57 can effect side chain preference at both
the P9 and P10 positions [27]. Lists of peptides known
to bind to particular human MHC alleles, and predicted
allele-specific peptide binding motifs, have been col-
lected in several databases, although quantitative data
on the MHC-peptide binding interaction are not included
[18, 19]. We scanned one such database, SYFPEITHI,
for sets of similar HLA-DR1 alleles that differ in the P10
pocket residues 57 and 60 and for which reliable
peptide binding motifs were available. DRB1*0401,
DRB1*0404, and DRB1*0405 form such a set. These
alleles differ only at positions 57 (Asp or Ser), 71 (Arg
or Lys), and86 (Gly or Val) (Figure 4). The polymorphism
at 71 is not expected to significantly influence peptide
side chain specificity, as both Arg71 and Lys71 form
a similar hydrogen bond with the peptide main chain
carbonyl at position 5, between the P4 and P6 pockets
Figure 3. Effect of Different Amino Acids at the P10 Position of [7, 12]. Residue 86 is found on the wall of the P1 pocket,
Peptides in Peptide Binding to HLA-DR1 and this polymorphism is expected to influence only
(A) MHC-peptide binding competition assay of a set of peptides the specificity at the P1 position [12, 17, 28]. Thus, the
that contained the AAYSDQATLLLXSPR sequence, where X is one pattern of substitutions at these positions allows the
of the 20 natural amino acids.
effects of the Asp/Ser polymorphism at 57 to be evalu-(B) Effect of each amino acid at the P10 position. Values represent
ated: preferences observed for DRB1*0405 that are notthe IC50 of the residue over the average IC50 for the entire peptide
shared by DRB1*0401 and DRB1*0404 can be attributedseries. The bar labeled “none” represents a peptide that ended at
the P9 residue (this residue is amidated). to the presence of Ser57. The peptide binding motif
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substitutions in other pockets, like the HLA-DRB1*04
set described above). The resulting proteins were pro-
duced by expression in E. coli inclusion bodies and
in vitro folding in the absence of peptide. The mutants
were characterized to ensure that the substitutions did
not result in gross alterations to the structure or to the
peptide binding activity. First, each of the mutants ex-
hibited a peptide-dependent decrease in gel filtration
elution volume (Figure S3A), which previously has been
described for HLA-DR1. The change results from a con-
formational alteration that accompanies the peptide as
the binding site converts from a more open empty form
to a more tightly packed closed form in the presence
of peptide [29]. Second, each of the mutants bound the
HA peptide (P10 Ala) with essentially identical apparent
affinity (Figure S3B). Each of the mutants was also able
to bind the CLIP peptide, a fragment of the class II-
associated invariant chain that associates with class
II MHC proteins during biosynthesis and intracellular
trafficking. Apparent affinities for CLIP (P10 Gln) were
similar but not identical, with D57V and D57V/Y60S bind-
ing more weakly (3 fold). Thus, the mutations do not
appear to have grossly altered the fold or activity of
HLA-DR1.
To assess the effects of introduction of polymorphicFigure 4. Analysis of Peptides that Bind to Different MHC Alleles
residues in the P10 pocket on the peptide binding affinityThe frequencies of different groups of amino acids at the P10 posi-
tion were calculated by using a list of peptides known to bind to and specificity at the P10 position, peptide binding com-
DRB1*0401, DRB1*0404, and DRB1*0404 from the SYFPEITHI data- petition assays were done for each mutant by using
base [18]. The aromatic group includes Trp, Tyr, and Phe; the hy- the AAYSDQATLLLXSPR series (Figure 5, Table S4). To
drophobic group includes Ile, Leu, Val, and Met; the small group
facilitate comparison with the HLA-DR1 preferences, theincludes Ala, Pro, and Gly; the polar group includes Thr, Ser, Cys,
bar graphs in Figure 5 are shown in the same order asAsn, and Gln; and the charged group includes His, Glu, Arg, Lys,
in Figure 3D. Clear differences were observed betweenand Asp. Sequence differences between the three alleles are indi-
cated; only 57 is in the P10 regions (each of the alleles has Tyr60). the P10 side chain specificities of the HLA-DR1 variants.
For example, asparagine at the P10 position promotes
binding to the D57A/Y60H and D57V/Y60S variants
for HLA-DR4 has been studied extensively [14, 17], but significantly decreases binding in HLA-DR1 D57A
allowing us to align a moderately sized set of known and D57V variants. Some general preferences are ap-
binders comprising 42 DRB1*0401 binding peptides, 14 parent for the entire set; for example, Phe, Leu, Trp, and
DRB1*0404 binding peptides, and 17 DRB1*0405 bind- Met bind well, while Ile and His bind poorly to each of
ing peptides, according to their expected peptide bind- the variants.
ing frame. In this analysis, we included only peptides for
which a single dominant binding register was apparent
(Table S3). While the databases do not contain quantita- Significance
tive binding data on these peptides, it is evident that
the alleles have selected sets of peptides that differ in MHC genes are the most polymorphic in the human
genome. This polymorphism results in different pep-the residue predicted in the P10 position, with the HLA-
DRB1*0405 binding set enriched in charged amino acid tide binding specificities for the corresponding allelic
variant proteins. Thus, different individuals will reactresidues at the expense of hydrophobic and aromatic
residues (Figure 4). Thus, the 57 polymorphism ap- differently to a set of peptides from a particular anti-
gen, with implications for vaccine design and suscep-pears to influence the P10 peptide binding specificity.
tibility to autoimmune and infectious diseases. Algo-
rithms that predict peptide binding to common humanHLA-DR1 with Polymorphic Substitutions in the
P10 Region Exhibits Altered P10 Specificity allelic variants are available and have found use in the
study of autoimmune target antigens, in the design ofTo evaluate in a more quantitative way the influence of
HLA-DR polymorphic residues on P10 specificity, we immunogenic and nonimmunogenic protein therapeu-
tics, and in development of subunit-based vaccines.constructed a series of P10 pocket variants of HLA-
DR1 (DRB1*0101) and evaluated their binding to the P10 For HLA-DR proteins, the most prevalent type of hu-
man class II MHC protein, such approaches generallypeptide libraries as described above. Single and double
amino acid replacements of polymorphic residues in account only for specificity at the P1–P9 positions of
peptide antigen. Here, we have investigated an inter-the P10 shelf (D57A, D57A/Y60H, D57V, and D57V/
Y60S) were introduced into HLA-DR1 so that their ef- action outside this region, at the P10 position, which
contributes significantly to the overall peptide bindingfects on P10 binding specificity could be isolated (natu-
rally polymorphic variants at these positions also have affinity. In a crystal structure of HLA-DR1 bound to a
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Figure 5. Influence of Different Amino Acids at the P10 Position in Peptide Binding to HLA-DR1 Mutants
Values represent the IC50 of the residue over the average IC50 of the entire AAYSDQATLLLXSPR peptide series for that particular HLA-DR1
mutant. The bar labeled “none” represents a peptide that ended at the P9 residue (this residue is amidated).
cell) insect cells as soluble empty  heterodimers, as describedpeptide antigen, we observed a shallow pocket that
previously [30]. For X-ray crystallography of the MHC-peptide com-accommodates the P10 side chain. The residues that
plex in the presence of the superantigen, the extracellular portionline this pocket are polymorphic among human HLA
of HLA-DR1 was produced by expression of isolated subunits in
variants. We prepared HLA-DR1 variants carrying the Escherichia coli inclusion bodies, followed by refolding in vitro as
polymorphic residues and analyzed their peptide bind- described previously [31]. Refolded HLA-DR1 was purified by immu-
noaffinity chromatography by using the conformation-specificing specificity. Amino acid changes at the P10 position
monoclonal antibody LB3.1, followed by gel filtration chromatogra-resulted in changes up to 50-fold in the apparent pep-
phy in phosphate-buffered saline (pH 6.8). The protein concentrationtide binding affinity as measured by a competition
was measured by UV absorbance at 280 nm by using 280 of 54,375assay. The P10 side chain binding specificity was sig-
M1 cm1 for empty HLA-DR1. SEC-3B2 superantigen was ex-
nificantly different for HLA-DR1 and for each of the pressed as a soluble protein in E. coli and isolated from the periplas-
variants. These results provide new data on peptide mic fraction as described previously [32].
selection by human class II MHC proteins and should
improve our ability to predict MHC allele-specific pep-
Construction and Analysis of HLA-DR1 Variants Carryingtide binding patterns and individual differences in im-
Single or Double Amino Acid Substitutions
munogenicity of protein therapeutics, autoimmune an- in the P10 Shelf
tigens, and vaccines. We used in vitro site-directed mutagenesis to make single or double
point mutations on the  chain of HLA-DR1 that corresponded to
Experimental Procedures polymorphic changes in the P10 pocket (QuikChange mutagenesis
system, Stratagene). For each reaction, a pLM1 [31] double-stranded
Peptide Synthesis vector carrying an insert of the  chain of HLA-DR1 was hybridized
Peptides were synthesized by using solid-phase F-moc (N-[9-fluore- to two synthetic oligonucleotides primers, both containing the desired
nyl]methoxycarbonyl) chemistry on a Symphony instrument (Protein mutations. The oligonucleotides, each complementary to opposite
Technology, Inc.). All peptides were amidated at the C terminus. strands of the vector, were extended during temperature cycling by
N-biotinylated peptides were prepared by coupling aminocaproyl- PfuUltra HF DNA polymerase (Stratagene), without primer displace-
(LC)-biotin (Anaspec) to the N terminus of the resin bound, side– ment. After the temperature cycling, the product was treated with
chain-protected peptide by using a standard amino acid coupling DpnI endonuclease (Stratagene) to digest the parent DNA template
procedure. The peptides were deprotected and cleaved from the resin and select for mutation-containing synthesized DNA. The vector
by a 2 hr treatment at room temperature with a mixture of trifluoroacetic DNA containing the desired mutations was transformed into XL1-
acid/H2O/thioanisole/phenol/dithiothreitol (82.5:5:5:5:2.5). The solution Blue supercompetent cells (Stratagene). Sequencing of five ran-
of peptides was precipitated with cold diethyl ether, and the crude domly chosen clones revealed only the desired mutations.
peptides were filtered, washed with ether, and dried in vacuum. The To make HLA-DR1-D57A, the primers used were 5-GACGGAGC
crude peptides were purified by high-performance liquid chroma- TGGGGCGGCCTGCTGCCGAGTATTGGAAC-3 (sense) and 5-GTT
tography (Vydac-C18). The purity and homogeneity of each peptide CCAATACTCGGCAGCAGGCCGCCCCAGCTCCGT-3 (antisense).
was checked by high-performance liquid chromatography (Vydac- For HLA-DR1-D57A/Y60H, the primers used were 5-GAGCTGGGG
C18) and MALDI-TOF mass spectrometry. Peptide concentrations CGGCCTGCTGCCGAGCACTGGAACAGCCAGAAGGAC-3 (sense)
were measured by absorbance at 280 nm (280nm  1280 M1 cm1) and 5-GTCCTTCTGGCTGTTCCAGTGCTCGGCAGCAGGCCGCC
in the case of peptides containing tyrosine or weredetermined by CCAGCTC-3 (antisense). The primers for HLA-DR1-D57V were
using amino acid analysis in the case of CLIP peptide. 5-GACGGAGCTGGGGCGGCCTGTGGCCGAGTATTGGAAC-3 (sense)
and 5-GTTCCAATACTCGGCCACAGGCCGCCCCAGCTCCGTC-3
(antisense). For HLA-DR1-D57V/Y60S, 5-GAGCTGGGGCGGCCTGTGProtein Expression and Purification
For peptide binding experiments and X-ray crystallography, the ex- GCCGAGTCTTGGAACAGCCAGAAGGAC-3 (sense) and 5-GTCCTT
CTGGCTGTTCCAAGACTCGGCCACAGGCCGCCCCAGCTC-3 (anti-tracellular portion of HLA-DR1 was produced from S2 (Schneider
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sense) were used. The HLA-DR1 mutants were expressed in E. coli tor, and minimization. A 2-fold noncrystallographic symmetry (NCS)
averaging improved the quality of the electron density map.inclusion bodies and refolded and isolated as described above for
wild-type HLA-DR1. In the case of HLA-DR1/AAYSDQATPLLLSPR/SEC3-2B2, coordi-
nates for another complex of E. coli-derived HLA-DR1 and SEC3-
3B2, carrying an N-methylated-designed peptide (Protein Data BankPeptide Binding Assays
code 1PYW) [26] were used as the search model to find a molecularA standard peptide binding competition assay [26, 33–35] was used
replacement solution. Waters and the peptide were removed fromto determine binding affinities of peptides to the HLA-DR1 molecule
the search model before use. After an initial rigid body refinement,and the mutants. Peptide-free wild-type HLA-DR1 produced in in-
eight rounds of refinement included minimization, B factor, andsect cells or a mutated form of HLA-DR1 produced in E. coli (25
minimization.nM) was mixed together with biotinylated Ha[306–318] peptide
For both structures, refinement was carried out with CNS [38],probe (Habio, 25 nM) and varying concentrations of unlabeled com-
and manual inspection and rebuilding were carried out with XtalViewpetitor peptide (1012–105M). The mixtures were incubated for
[39]. Waters were added to the refined molecule by using CNS. The3 days at 37C in 100 mM sodium phosphate buffer at pH 5.5,
final models were verified for distortions on the secondary structurecontaining 50 mM NaCl, 1 mg/ml PMSF, 37 g/ml iodoacetamide,
features with Procheck [40]. LSQKAB [41] was used to determine10 mM EDTA, 0.02% NaN3, and 0.5 mg/ml octylglucoside, followed
RMSD values for aligned coordinate sets.by detection of bound, biotinylated peptide using an immunoassay
that employed anti-DR1 capture antibody LB3.1 and alkaline phos-
MHC-Peptide Database Analysisphatase-labeled streptavidin. IC50 values were obtained by fitting a
The SYFPEITHI database of known MHC binding peptides [18] andbinding curve to the plots of fluorescence versus concentration of
the IMGT HLA sequence database [15] were examined to find setscompetitor peptide. The IC50 value for the control Ha peptide in-
of similar HLA-DR1 alleles that differed in the P10 pocket residuescluded in each assay was 29  14 nM (n  8).
and for which reliable motifs and many known peptide binders wereA direct binding assay was used to determine binding abilities of
available. HLA-DRB1*0401, HLA-DRB1*0404, and HLA-DRB1*0405HLA-DR1 mutants. The assay was performed for 3 days at 37C in
were selected for further analysis. HLA-DR allele-specific bindingthe same buffer as described above; constant concentration of the
peptides from the SYFPEITHI databases generally were used with-proteins (25 nM) were used, and the range of concentrations of
out further alignment, although multiple-length variants of the samebiotinylated peptides depended on the binding affinity of the particu-
antigen and some ambiguous alignments were deleted. Residueslar peptide (1011–106 for tight binders and 1011–102 for weak
predicted to bind into the P10 pocket were identified. A Fisher-Free-binders). The incubation was followed by immunoassay as de-
man-Halton Exact Test [42] revealed that the association betweenscribed above.
MHC alleles and residues at the P10 position approached signifi-
cance (p  0.056). To gain some insight into the nature of the allele
Crystallization specificity, residues were grouped by generic side chain properties:
HLA-DR1 peptide bound complexes were prepared by incubating aromatic (Trp, Tyr, Phe), hydrophobic (Ile, Leu, Val, Met), small (Ala,
purified empty HLA-DR1 (1–5 M) with at least 5-fold molar excess Pro, Gly), polar (Thr, Ser, Cys, Asn, Gln), and a charged group (His,
peptide for 3 days at 37C in phosphate-buffered saline with 0.02% Glu, Arg, Lys, Asp), and the frequency of each group was calculated
sodium azide. The complex was purified by gel filtration to remove for each allele.
aggregates and free peptide. Crystals of HLA-DR1/AAYSDQAT
PLLLSPR complex were grown at room temperature by the vapor
Supplemental Data
diffusion method in 10% polyethylene glycol 6000, 100 mM glycine
Supplemental Data including additional information regarding the
(pH 4.0), with 1 l precipitant solution mixed with 1 l 10 mg/lL. For
crystal structures described and data/values used in the analysis
X-ray diffraction experiments, the crystal was soaked in mother
of the P10 region of HLA-DR and the generation of figures are
liquor with 25% glycerol for 2 min and flashed cooled in liquid
available at http://www.chembiol.com/cgi/content/full/11/10/1395/
nitrogen. HLA-DR1 was isolated from insect cells.
DC1.
For the HLA-DR1/AAYSDQATPLLLSPR/SEC3-3B2 crystal struc-
ture, purified HLA-DR1/AAYSDQATPLLLSPR complex was mixed
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